[1] Sloan DJ, Wood MJ, Charlton HM.The immune response to intracerebral neural grafts.Trends Neurosci. 1991;14(8): 341-346.
[2] Nicholas MK, Antel JP, Stefansson K, et al.Rejection of fetal neocortical neural transplants by H-2 incompatible mice.J Immunol. 1987;139(7):2275-2283.
[3] Lampson LA. Molecular bases of the immune response to neural antigens. Trends Neurosci. 1987;10:211-216.
[4] Ying Ma, Jiuping Wang, Bin Yuan,et al.HLA-A2 and B35 Restricted Hantaan Virus Nucleoprotein CD8+ T-Cell Epitope-Specific Immune Response Correlates with Milder Disease in Hemorrhagic Fever with Renal Syndrome.PLoS Negl Trop Dis. 2013;7(2):e2076.
[5] Juarez V, Pasolli HA, Hellwig A, et al.Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice.Open Virol J. 2012;6: 270-276.
[6] Sachiko Yoshimura, Takuya Tsunoda, Ryuji Osawa, et al. Identification of an HLA-A2-Restricted Epitope Peptide Derived from Hypoxia-Inducible Protein 2 (HIG2).PLoS One. 2014;9(1):e85267.
[7] Zhang X, Lin A, Zhang JG, et al.Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma.Int J Cancer. 2013;132(1):82-89.
[8] Xia R, Qiu HY, Zhang WP, et al.Dynamic monitoring of graft-versus-host disease after allogeneic peripheral blood stem cell transplantation by soluble HLA-I antigen detection. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(6):687-690,695.
[9] Michael Campoli, Soldano Ferrone. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Published in final edited form as: Semin Immunopathol. 2011;33(4):321-334.
[10] Marinova-Mutafchieva L, Chakalova G.Local immunosuppression determined by class II HLA antigen expression in patients with preclinical cervical carcinoma.Eur J Gynaecol Oncol. 1992;13(6):494-497.
[11] Tang YY, Tang ZH, Zhang Y,et al.The Fusion Protein of CTP-HBcAg18-27-Tapasin Mediates the Apoptosis of CD8(+)T Cells and CD8(+) T Cell Response in HLA-A2 Transgenic Mice.Hepat Mon. 2014;14(2):e16161.
[12] Seyed N, Zahedifard F, Safaiyan S,et al. In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.PLoS Negl Trop Dis. 2011;5(9):e1295.
[13] Yan Y, Chen Y, Yang F,et al. HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells.Int J Immunopathol Pharmacol. 2007;20(1):75-89.
[14] Panigrahi A, Gupta N, Siddiqui JA,et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.Hum Immunol. 2007;68(5):362-367.
[15] Yoshimura S, Tsunoda T, Osawa R,et al. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia- inducible protein 2 (HIG2).PLoS One. 2014;9(1):e85267.
[16] 段德义,张海燕,徐群渊,等.反义HLA A2和GDNF共表达逆转录病毒载体的构建和鉴定[J].神经解剖学杂志,2005,21(2):103-107.
[17] Sawada Y, Komori H, Tsunoda Y,et al. Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer.Oncol Rep. 2014;31(3):1051-1058.
[18] 李颖,杨慧,徐群渊,等.反义HLA A2 cDNA抑制人成纤维细胞于大鼠脑内移植后的免疫排斥反应[J].神经解剖学杂志, 2005, 21(2):113-118.
[19] Huang YH, Terabe M, Pendleton CD,et al. Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.PLoS One. 2013;8(6):e64365.
[20] Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today. 2006;11(1-2):67-73.
[21] Markmann JF, Bassiri H, Desai NM,et al. Indefinite survival of MHC class I-deficient murine pancreatic islet allografts. Transplantation. 1992;54(6):1085-1089.
[22] Tan AC, La Gruta NL, Zeng W, et al. Precursor frequency and competition dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice.J Immunol. 2011;187(4):1895-1902.
[23] Vali B, Tohn R, Cohen MJ,et al.Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses.J Virol. 2011;85(1):254-263.
[24] Horowitz A, Li X, Poles MA, et al.Use of immobilized HLA-A2: Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response. Scand J Immunol. 2009;70(5):415-422.
[25] Fagerberg T, Zoete V, Viatte S,et al. Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships.PLoS One. 2013;8(7):e65590.
[26] Li L, Muzahim Y, Bouvier M.Crystal structure of adenovirus E3-19K bound to HLA-A2 reveals mechanism for immunomodulation. Nat Struct Mol Biol. 2012;19(11):1176-1181.
[27] Lee MK 4th, Huang X, Jarrett BP,et al.Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.Transplantation. 2003;75(8):1415-1422.
[28] Duan WM, Westerman M, Flores T,et al. Survival of intrastriatal xenografts of ventral mesencephalic dopamine neurons from MHC-deficient mice to adult rats.Exp Neurol. 2001;167(1):108-117.
[29] Guo Z, Zhang H, Rao H,et al. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS One. 2012;7(6):e38390.
[30] Veng LM, Bjugstad KB, Freed CR,et al. Xenografts of MHC-deficient mouse embryonic mesencephalon improve behavioral recovery in hemiparkinsonian rats.Cell Transplant. 2002;11(1):5-16.
[31] Pakzaban P, Deacon TW, Burns LH,et al. A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience. 1995;65(4):983-996.
[32] Ma Y, Wang J, Yuan B,et al.HLA-A2 and B35 restricted hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response correlates with milder disease in hemorrhagic fever with renal syndrome. PLoS Negl Trop Dis. 2013;7(2):e2076.
[33] Faustman D, Coe C. Prevention of xenograft rejection by masking donor HLA class I antigens.Science. 1991;252(5013): 1700-1702.
[34] Li X, Faustman D.Use of donor beta 2-microglobulin-deficient transgenic mouse liver cells for isografts, allografts, and xenografts.Transplantation. 1993;55(4):940-946.
[35] Straetemans T, van Brakel M, van Steenbergen S,et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Clin Dev Immunol. 2012;2012:586314.
[36] Juarez V, Pasolli HA, Hellwig A,et al.Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice.Open Virol J. 2012;6: 270-276.
[37] Rezvan H, Rees R, Ali S. Immunogenicity of MHC Class I Peptides Derived from Leishmania mexicana Gp63 in HLA-A2.1 Transgenic (HHDII) and BALB/C Mouse Models. Iran J Parasitol. 2012;7(4):27-40.
[38] Southwood S, Solomon C, Hoof I,et al. Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities. Immunogenetics. 2011;63(5):275-290.
[39] Sawada Y, Komori H, Tsunoda Y,et al. Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncol Rep. 2014;31(3):1051-1058.
[40] Hunt DF, Henderson RA, Shabanowitz J, et al. Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science. 1992; 255:1261-1263.
[41] Samandary S, Kridane-Miledi H, Sandoval JS,et al. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: Implication for the development of an universal CD8+ T-cell epitope-based vaccine.Hum Immunol. 2014.[Epub ahead of print] |